Brief: Syndax Pharmaceuticals Q2 EPS USD -0.8
01/08/2024 21:06
Aug 01 (Reuters) - Syndax Pharmaceuticals Q2 operating income USD -74.216 million. * Q2 operating expenses USD 77.716 million * Q2 net income USD -68.063 million * Q2 cash & investments USD 454.6 million
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million